Table 1.

Bone density and metabolic assessment for secondary causes of bone loss in perimenopausal breast cancer women with hip fractures

AgeStageChemoMedicationsBMD spine (gm/cm2)Tscore spineBMD hip (gm/cm2)T-score hipOsteoporosis therapy (months)25 OH Vitamin D (ng/mL)PTH24 hour urine calcium (mg/day)
50IIBAdriamycin CytoxanArimidex0.921–1.20.712–1.556.537175
54IAdriamycin CytoxanNone0.809–2.20.750–1.6Alendronate (24)45.827267
52IAdriamycin CytoxanNone0.628–3.80.566–3.014.92151
59IIAdriamycin CytoxanArimidex0.859–1.70.671–2.322.177184
54IAdriamycin CytoxanArimidex0.866–1.60.736–1.721.127270
49IIAdriamycin CytoxanArimidex0.875–1.60.780–1.3